ConferenceMay 12, 2026168 days ago
First real-world RYTELO study in LR-MDS to be presented at EHA 2026
Geron presented data on RYTELO (imetelstat) for lower-risk myelodysplastic syndromes at a medical meeting on May 12, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
DetailsData presented at a medical meeting
- Company
- Geron Corporation GERN
- Drug
- RYTELO (imetelstat)
- For
- lower-risk myelodysplastic syndromes
- Stage
- real-world evidence (post-approval)
- When
- May 12, 2026
- Source note
- Geron announced that the first real-world evidence study of imetelstat in lower-risk MDS — an investigator-sponsored Moffitt Cancer Center analysis in heavily transfusion-dependent, post-luspatercept patients — would be presented at the EHA 2026 Congress; results were generally consistent with the Phase 3 IMerge trial.
- Checked
- Checked by a person when it was added
Check the sourcesdon’t take our word for it
- Source: stocktitan.net ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- GERN headlines on this site
Geron Corporation
1 upcoming · 2 past catalysts
More from GERN
Geron expects to report results from its Phase 3 study of imetelstat (RYTELO) for JAK-inhibitor relapsed/refractory intermediate-2/high-risk myelofibrosis in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- IMpactMF Phase 3 interim analysis (overall survival) in relapsed/refractory myelofibrosis · Clinical trial results (readout / topline data)
- Drug
- imetelstat (RYTELO)
- For
- JAK-inhibitor relapsed/refractory intermediate-2/high-risk myelofibrosis
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Prior guidance placed the interim OS analysis in 2H 2026; on the Q2 2026 call management said projected timelines are unchanged but it is evaluating a modification to the interim event threshold, calls a positive interim an upside scenario, and keeps final OS analysis in 2H 2028 as base case. Timing risk is real.
- Checked
- Checked by a person when it was added
- Verify it
- Source: fool.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- GERN headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page